ABL1 and small cell lung carcinoma: In addition and in sharp contrast to NSCLC, for which survival has improved remarkably in the past few decades due to the development of EGFR, ROS1, and ALK inhibitors among others, no major developments have been made in SCLC treatment, including targeted agents, such as EGFR-TKI, BCR-ABL TKIs, or mTOR inhibitors9–11.